Literature DB >> 32038977

68Ga-PSMA-11 PET accuracy in recurrent prostate cancer.

Silvi Telo1, Andrea Farolfi1, Paolo Castellucci1, Stefano Fanti1.   

Abstract

Entities:  

Year:  2019        PMID： 32038977      PMCID： PMC6987587          DOI： 10.21037/tau.2019.07.13

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  15 in total

1.  A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

Authors:  Michael McCarthy; Roslyn Francis; Colin Tang; Joanne Watts; Andrew Campbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-16       Impact factor: 7.038

2.  Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Sangwon Han; Sungmin Woo; Yeon Joo Kim; Chong Hyun Suh
Journal:  Eur Urol       Date:  2018-04-18       Impact factor: 20.096

3.  (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Authors:  Cristina Nanni; Lucia Zanoni; Cristian Pultrone; Riccardo Schiavina; Eugenio Brunocilla; Filippo Lodi; Claudio Malizia; Matteo Ferrari; Patrizio Rigatti; Cristina Fonti; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-10       Impact factor: 9.236

Review 4.  Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

Authors:  Laura Evangelista; Andrea Guttilla; Fabio Zattoni; Pier Carlo Muzzio; Filiberto Zattoni
Journal:  Eur Urol       Date:  2012-09-25       Impact factor: 20.096

Review 5.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Marlon Perera; Nathan Papa; Daniel Christidis; David Wetherell; Michael S Hofman; Declan G Murphy; Damien Bolton; Nathan Lawrentschuk
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

6.  Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.

Authors:  Frederik A Verburg; David Pfister; Axel Heidenreich; Andreas Vogg; Natascha I Drude; Stefan Vöö; Felix M Mottaghy; Florian F Behrendt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-12       Impact factor: 9.236

7.  Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.

Authors:  P Mhawech-Fauceglia; S Zhang; L Terracciano; G Sauter; A Chadhuri; F R Herrmann; R Penetrante
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

Review 8.  68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.

Authors:  Julia Corfield; Marlon Perera; Damien Bolton; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2018-01-17       Impact factor: 4.226

9.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Authors:  Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

Review 10.  Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Authors:  Frédéric E Lecouvet; Daniela E Oprea-Lager; Yan Liu; Piet Ost; Luc Bidaut; Laurence Collette; Christophe M Deroose; Karolien Goffin; Ken Herrmann; Otto S Hoekstra; Gem Kramer; Yolande Lievens; Egesta Lopci; David Pasquier; Lars J Petersen; Jean-Noël Talbot; Helle Zacho; Bertrand Tombal; Nandita M deSouza
Journal:  Lancet Oncol       Date:  2018-10-01       Impact factor: 41.316
View more
  2 in total

1.  Systematic review & meta-analysis of positron emission tomography/computed tomography and bone scan in the diagnosis of prostate lesions.

Authors:  Jiafu Wang; Yue Han; Lin Lin; Linhan Zhang; Jin Li; Huiqi Gao; Peng Fu
Journal:  Transl Androl Urol       Date:  2021-11

2.  Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [68Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy.

Authors:  Paulina Cegla; Marta Wojewódzka; Izabela Gorczewska; Wioletta Chalewska; Grażyna Łapińska; Paweł Ochman; Agata Sackiewicz; Marek Dedecjus
Journal:  Diagnostics (Basel)       Date:  2022-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.